Message From The Chairman
Welcome to the Latona Life Sciences website. Thank you for taking the time to visit our website to learn more about our company.
Latona Life Sciences, Inc. is poised to take advantage of the trend towards development of therapeutic pharmaceutical and biotech products. There is substantial growth opportunity for a unique specialty pharmaceutical firm such as Latona to capture market share and develop a profitable business. Specialty pharmaceutical companies that remain focused on identifying key therapeutic orphan drug markets and using targeted marketing, rapidly drive clinical trial progression, regulatory approval and commercialization.
Latona has acquired the rights to Oralgam™, a product that we expect will compete in several orphan drug markets that are underserved by existing therapies. This product will be utilized by a select patient population and prescribed by a specialized physician group. This targeted approach significantly reduces the development costs, approval time and marketing and sales costs which will accelerate the profitability of the Company.
Oralgam™ is the first oral formulation of human immunoglobulin approved for testing in humans by the FDA. In contrast to intravenous or intramuscular preparations, Oralgam™ provides a source of protective mucosal immunity to intestinal surfaces exposed to an estimated 1014 microbial organisms derived from more than 500 species inhabiting the gut. Extensive processing and purification during manufacturing ensures that Oralgam™ is free of viruses or other pathogens. In addition, results from our clinical studies to date in more than two hundred adults and children show that oral immunoglobulin can be administered over periods of up to one year without the side effects.
Oralgam™ is a product with potential to serve the Juvenile Idiopathic Arthritis market, and has a development platform potential for treatment of a number of orphan diseases as well as many of the over 80 autoimmune diseases.
Each clinical trial with Oralgam™ takes Latona closer to marketing approval. Continuing research is helping us to identify new and exciting areas to pursue in future clinical studies.
Oralgam™ and its use in JIA have been designated as an Orphan Drug by the FDA. Orphan Drug Status has many advantages but two are of significant importance, namely, market exclusivity for seven (7) years post regulatory approval and an expedited review cycle from the FDA.
At Latona Life Sciences, we share a common mission to engage in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is dedicated to the development and commercial marketing of products in key therapeutic orphan drug markets.
Thank you for taking an interest in us ~ we look forward to keeping you informed.